IJsselstein Study of Central Obesity

IJsselstein Study of Central Obesity - IJSCO-2

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33262

Enrollment

673

Registered

2009-10-28

Start date

2009-11-02

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

insulin resistance syndrome metabolic syndrome

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Central obesity measured during the screening for the metabolic syndrome in 2006/2007

Exclusion criteria

Exclusion criteria: Pregnancy

Design outcomes

Primary

Measure	Time frame
The main endpoint is the remission of the metabolic syndrome in the 473 people with screen-detected metabolic syndrome. Metabolic syndrome will be determined according to NCEP ATP III-criteria.	—

Secondary

Measure	Time frame
- Changes in the separate components of the metabolic syndrome: waist circumference, blood pressure, HDL cholesterol, triglycerides and fasting glucose - Changes in lifestyle, with regard to smoking, alcohol use and physical activity - The development of type 2 diabetes or cardiovascular disease since the screening - Cardiovascular medications that were prescribed after the screening - Illness perception with regard to obesity	—

Measure

Time frame

- Changes in the separate components of the metabolic syndrome: waist circumference, blood pressure, HDL cholesterol, triglycerides and fasting glucose - Changes in lifestyle, with regard to smoking, alcohol use and physical activity - The development of type 2 diabetes or cardiovascular disease since the screening - Cardiovascular medications that were prescribed after the screening - Illness perception with regard to obesity

—

Countries

Netherlands

Outcome results